Oligoarray analysis of a matched pair of prostate cancer and normal cell lines derived from the same radical prostatectomy specimen identified 113 candidate hypomethylated genes that were overexpressed in the cancer cells and contained CpG islands. Hypomethylation of wingless-related MMTV integration site 5A (WNT5A), S100 calcium-binding protein P (S100P) and cysteine-rich protein 1(CRIP1) was confirmed in the cancer cells by bisulfite sequencing. Treatment of the corresponding normal prostate epithelial cells 1542-NPTX with the DNA methyltransferase inhibitor 5-Aza-2 0 -deoxycytidine (5-aza-CdR) induced higher levels of mRNA expression and partial loss of methylation on these genes. Primary prostate cancers were tested using methylation-specific polymerase chain reaction. WNT5A was hypomethylated in 11/17 (65%) tumors, S100P in 8/16 (50%) and CRIP1 in 13/20 (65%). Bisulfite sequencing of a section of the 5 0 untranslated region (UTR) of WNT5A revealed that three CpG sites (15, 24 and 35) were consistently methylated (93%) in the normal cell line and normal tissues, but not in the prostate cancer cell line and eight primary prostate cancers. Multiple putative binding sites for the transcription factors SP1 and AP-2 were found adjacent to CpG sites 15 and 24. A putative c-Myb binding site was located within the CpG site 35. Anti-c-Myb antibody co-precipitation with WNT5A was methylation-sensitive in 1542-NPTX cells. It is likely that an epigenetic mechanism regulates WNT5A expression in prostate cancer.
Introduction
Prostate cancer is the second leading cause of cancer death in men in the United States (Jemal et al., 2005) .
Among a variety of environmental and genetic factors involved in the development of prostatic cancer, changes in the methylation status of CpG islands of gene promoter regions are widely reported (Jones and Laird, 1999) . Tumor-specific transcriptional silencing of genes in human tumors by promoter hypermethylation is well documented (Esteller et al., 2001 ). Epigenetic silencing is also known to be a frequent event in prostate cancer and occurs in genes that are involved in cell-cycle control, DNA damage repair, signal transduction and hormonal response such as GSTP1, MGMT, APC, CDH1, CD44, RASSF1A and AR (reviewed by Li et al., 2004) .
However, comparatively little is known about the role of hypomethylation in the initiation and development of tumors, particularly in prostate cancer. An association between hypomethylation and gene activation in cancer has been reported in a number of genes in various types of cancer, for example, hypomethylation of cyclin D2 and maspin in gastric cancer (Akiyama et al., 2003; Oshimo et al., 2003) , MN/CA9 in renal cancer (Cho et al., 2001) , and SNCG/BCSG1 in breast and ovarian cancer (Gupta et al., 2003) . Sato et al. (2003) found seven genes (including S100A4, mesothelin (MSLN) and prostate stem cell antigen (PSCA)) that appeared to be hypomethylated in pancreatic cancer. In mice carrying a hypomorphic Dnmt1, a genome-wide hypomethylation was observed in addition to animals developing aggressive T-cell lymphomas at age of 4-8 months, indicating that DNA hypomethylation plays a causal role in tumor formation (Gaudet et al., 2003) . Although global hypomethylation was suggested to be a common event in prostate cancer (Brothman et al., 2005) , very little information exists regarding the target genes regulated by hypomethylation in prostate cancer (Ogishima et al., 2005; Tokizane et al., 2005) . In this study, we identify upregulation of WNT5A, S100P and cysteine-rich protein 1 (CRIP1) in prostate cancers to be associated with 5 0 untranslated region (UTR) hypomethylation. The candidate genes were originally identified from an oligoarray study of a paired normal (1542-NPTX) and cancer (1542-CP 3 TX) cell lines from a localized human prostate cancer (Bright et al., 1997) using Affymetrix (Santa Clara, CA, USA) HU133A arrays (22 500 transcripts including approximately 18 500 known genes). RNA from three independent cell cultures of 1542-CP 3 TX was compared to three samples from cultures of 1542-NPTX (see Supplementary Information for detailed methodology) using a 3 Â 3 matrix analysis utilizing the DNA mining tool (Affymetrix), resulting in nine comparisons. A total of 346 genes showed downregulation and 186 genes displayed upregulation in 1542-CP 3 TX cells, based upon the criterion of two-fold (or greater) difference in expression in at least 6 out of 9 cross comparisons. The oligoarray data were validated by reverse transcription-(PCR) analysis (data not shown).
A search was conducted of the first exon and approximately 5 kb upstream of 186 upregulated genes using SOURCE and CpG island searcher software.
Of the 186 genes, 113 had CpG islands in their upstream (promoter) region and/or within the first exon (Supplementary Table 1 ). Several of these genes are reported to be overexpressed and regulated by hypomethylation, including CYP1B1 in prostate cancer (Tokizane et al., 2005) and S100P, PSCA, MSLN and CRIP1 in pancreatic cancer (Sato et al., 2003 (Sato et al., , 2004 .
The expression of WNT5A and CRIP1 was increased by over 50-fold and that of S100P by 12-fold (Supplementary Table 1, Figure 1a ) in 1542-CP 3 TX compared to 1542-NPTX. CRIP1 and S100P are known to be upregulated in other cancers (Gibadulinova et al., 2005; Ishii et al., 2005) . Association of hypomethylation and upregulation of both S100P and CRIP1 were identified in pancreatic cancer (Sato et al., 2003 (Sato et al., , 2004 . The upregulation of WNT5A has also been shown previously in various tumors, including prostate cancer (Iozzo et al., 1995) . However, the methylation status of these three genes has not been studied in prostate cancer.
We therefore investigated the methylation status of these genes in prostate cancer cell lines and cancer tissues. The methylation status of S100P and CRIP1 in 1542-NPTX cells was examined by sequencing of PCRamplified sodium bisulfite-treated DNA in the following manner: S100P was amplified from À498 to þ 215 (relative to the gene transcription start site þ 1) and CRIP1 from À433 to þ 81. The PCR products were cloned and more than eight clones sequenced to identify methylated cytosine residues. Sequencing showed that the majority of the CpG sites were methylated on S100P and CRIP1 (Supplementary Figure 1) . S100P is implicated in cancer development and progression. Overexpression is also associated with the progression of prostate cancer (Mousses et al., 2002) . CRIP1 belongs to the LIM family and is a tissue-specific developmentally regulated protein (Levenson et al., 1993) . It has been suggested that CRIP1 may be involved in protein-protein interactions with transcription factors (Jurata et al., 1996) . Overexpression of the proto-oncogene ERBB2 is associated with a poor prognosis in invasive ductal breast cancer. Upregulation of ERBB2 also results in overexpression of S100P and CRIP1, suggesting that S100P and CRIP1 may play a role in ERBB2-related oncogenesis (Mackay et al., 2003) .
WNT5A belongs to a large family of secreted glycoproteins, may act as an oncogene and is involved in intracellular signalling that modulates transcription of various target genes (Miller et al., 1999) . It has also been suggested that WNT5A may act as a tumor suppressor gene as it inhibits B-cell proliferation and functions as a tumor suppressor in hematopoietic tissue (Liang et al., 2003) . Pukrop et al. (2006) suggested that these contradictory findings imply that the functions of WNT5A could be modified by additional regulators. Using genomic DNA from 1542-NPTX, the 5 0 -UTRregion of WNT5A was sequenced from þ 91 to þ 686 of the first exon, 75 bases upstream of the start codon ATG site. The sequencing revealed (Figure 2a ) that there are 35 CpG sites within this region and six predicted transcription factor binding sites. In contrast to CRIP1 and S100P, however, only about 10% of the CpG sites were methylated in WNT5A.
Methylation profile of the 35 CpG sites in both cell lines is shown in Figure 2b . In 11 clones of 1542-NPTX cells, 12% (43/385) of CpG sites were methylated compared to the 3.9% (15/385) in 1542-CP 3 TX clones. There was at least one of the CpG sites 15, 24 or 35 methylated in each clone, with 7/11 (64%) clones in CpG site 15, 5/11 (45%) in CpG site 24 and 6/11 (55%) in CpG site 35 in 1542-NPTX. In 1542-CP 2 TX cells, however, 5/11 (45%) of colonies showed no methylation at any CpG site. Furthermore, there was no methylation at CpG sites 15 and 24 in all 11 clones. There were also fewer clones methylated on CpG site 35 in 1542-CP 2 TX cells (4/11, 36%).
Although more methylated CpGs were seen in 1542-NPTX cells, the methylation was infrequent and restricted to specific sites and consequently the functional significance was not clear. To determine if the methylation of CpG sites 15, 24 and 35 influences transcription, we searched for putative transcription factor binding sites using Transcription Element Search 0 -azaCdR for 24 h (NP þ ). These three genes are upregulated in the cancer cells (PCR cycles: 38 for WNT5A, 34 for CRIP1 and 28 for S100P) and are also upregulated in normal cells following treatment with 5 0 -aza-CdR (with 38 PCR cycles for WNT5A, 36 for CRIP1 and 30 for S100P). First-strand cDNA was normalized with respect to expression of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and subsequently used to assess expression levels in 1542-NPTX and 1542-CP 3 TX cell lines. PCR primers are listed in Supplementary Table 2. System (TESS) software. Three putative SP1 and two AP-2 binding sites were adjacent to CpG sites 15 and 24 (Figure 2a) . SP1 is involved in the control of cell growth and morphogenetic pathways (Black et al., 1999) . Methylation outside of the consensus sequence for SP1 induced a significant decrease in SP1 binding, leading to a reduced target gene expression (Zhu et al., 2003) . AP-2 regulates genes involved in various biological functions, including p21 WAF/CIP (Zeng et al., 1997) , transforming growth factor-a (Wang et al., 1997) , estrogen receptor (McPherson et al., 1997) , and tyrosine kinase receptor gene c-KIT (Huang et al., 1998) . AP-2 also negatively regulates a number of genes, including c-myc (Gaubatz et al., 1995) and c-/EBP-a (Jiang et al., 1998) . No predicted transcription factor binding sites were found within CpG sites 15 and 24. Furthermore, the sequence 5 0 -CCGTTG-3 0 including the CpG site 35 (underlined) fitted the consensus sequence YAACNG, a DNAbinding site for the proto-oncogene c-Myb (Ording et al., 1996) .
Myb belongs to a family of transcription factors that regulate transcription of various genes involved in the control of the cell cycle and differentiation and suppression of apoptosis (Frampton et al., 1996) , hematopoiesis (Mucenski et al., 1991) and T-cell development (Bender et al., 2004) and transcription regulation (Lang et al., 2005) . In addition, DNA binding by c-myb protein is known to be methylation-sensitive on the promoter region of myb-inducible mim-1 gene (Klempnauer, 1993) . We used the chromatin immunoprecipitation (ChIP) assay to investigate how methylation of CpG site 35 influences the binding of c-Myb. To determine if CpG sites 15, 24 and 35 are hypomethylated in primary prostate cancer, we sequenced this region of the genomic DNA from three normal and eight prostate cancer samples by bisulfite sequencing (5 clones from each sample). The methylation status of the prostate tissue samples was consistent Eleven clones were sequenced from each cell line and five clones were sequenced from normal and prostate cancer tissues. The arrows indicate the CpG sites at 15, 24 and 35 respectively. These sites were consistently methylated in the normal cell line and tissues, but not in the prostate cancer cell line and tissues. NP1, NP2 and NP3 are normal prostate tissues. CP1, CP2, CP3, CP4, CP5, CP6, CP7 and CP8 are prostate cancer tissues. NP is 1542-NPTX, CP is 1542-CP 3 TX. DNA samples were bisulfite modified using CpGenome DNA Modification Kit (Intergen, Purchase, NY, USA) according to the manufacturer's instructions. Bisulfite-treated DNA was then subjected to PCR. Two microliters of PCR product was cloned into PCRII-TOPO vector using the TOPO TA Cloning kit (Invitrogen, Paisley, UK). Five to 11 clones containing inserts were sequenced by Qiagen. PCR primers are listed in Supplementary Table 2 .
Hypomethylated genes in prostate cancer Q Wang et al with that of the cell lines (Figure 2b) . A total of 13% (66/525) of CpG sites were methylated in the three normal tissue samples compared to 4.8% (67/1400) in the eight tumor samples. All of the normal samples showed methylation at CpG sites 15, 24 and 35 in 14/15 (93%) clones. In contrast, only 2/8 (25%) cancer samples, represented by 3/40 (7.5%) clones, displayed any methylation at CpG 15, 24 and 35, whereas 8/40 (20%) clones were methylated at CpG 35 (Figure 2b ).
Further confirmation of the hypomethylation of the 5 0 UTR-regions of CRIP1, S100P and WNT5A was obtained by using methylation specific PCR (MSP) (Herman et al., 1996) . The methylation status was classified by the relative methylation level (RML) (Sato et al., 2004 ). Of 17 cancers tested for WNT5A, the RML of 11 (65%) cancers was o40% and four (24%) was >60%, and two samples showed RML between 40 and 60%. Of 16 cancers tested for S100P, the RML of eight (50%) samples was o40%, seven (44%) was >60% and one sample had RML between 40 and 60%. Of 20 cancers tested for CRIP1, 13 (65%) samples had RML o40%, four (20%) was >60%, and three samples had RML between 40 and 60% (Figure 4, Supplementary  Figure 2) .
To determine the role of methylation in the transcriptional regulation of these genes, we examined mRNA expression in 1542-NPTX cells after treatment with the DNA methyltransferase inhibitor 5-aza-CdR. RT-PCR revealed that treatment with 5-aza-CdR resulted in increased expression of all three genes (Figure 1b) . Treatment with 5-aza-CdR also led to a partial loss of methylation of all three genes, as judged by MSP PCR (Figure 4 ). These findings suggest that DNA methylation may be involved in the transcriptional regulation of these three genes.
This study is the first evidence that WNT5A, S100P and CRIP1, which have been previously implicated in cancer progression, are regulated at the transcriptional level in prostate cancer by an epigenetic mechanism, namely hypomethylation. In this study, we examined only the methylation status of exon 1 of the WNT5A gene. The upregulation of mRNA expression and the partial loss of methylation in normal prostate cell line after 5-aza-CdR treatment indicate that de-methylation of CpG sites 15 and 24 (the MSP primers include those two sites) are associated with mRNA overexpression. The influence of the methylated CpG sites on the affinity of SP1, AP2 and c-Myb binding and the correlation with gene expression requires further investigation. Although other mechanisms may be involved in the upregulation of WNT5A in prostate cancer cells, our Table 2 . Immunoprecipitate (5 ml) was used for 33 cycles of amplification with the annealing temperature at 651C. Figure 4 Methylation-specific PCR of WNT5A, S100P and CRIP1. NP, 1542-NPTX; CP, 1542-CP 3 TX; NP þ : treated 1542-NPTX; U, unmethylated PCR products; M, methylated PCR products. NP cells showed predominantly methylated bands, while CP cells exhibited more unmethylated products. Partial loss of methylated products can be seen on NP þ cells compared to the NP cells. In the three normal tissue samples, more methylated products were amplified, while in the five cancer samples unmethylated bands predominate. Cancer tissue was obtained from 20 radical prostatectomy samples. The pathological stage of all the patients was pT3a. The pre-operative serum PSA levels were in the range 4.3-18 ng/ml. The Gleason scores were 6 or 7. The radical prostatectomy wholemounts of each sample were examined by microscopy and areas containing at least 70% of cancer cells were marked by a consultant histopathologist. Areas of cancer of >0.5 cm 2 were scraped off within the region marked. When the tumor area was very small (o0.5 cm 2 ) the cancer tissue was obtained by laser capture microdissection. Normal prostate tissue was obtained from the same sections. Each DNA sample (0.5-1.0 mg) was bisulfite modified using CpGenome DNA Modification Kit (Intergen, Purchase, NY, USA) according to the manufacturer's instructions. The PCR primers are listed in Supplementary Table 2. PCR products were resolved on 2% agarose gels and visualized using ethidium bromide staining. The intensity of resulting bands was analysed by the GeneGenius Imaging System (Syngene, Cambridge, UK). data demonstrate that DNA methylation can modulate WNT5A expression. To understand further the extent of epigenetic regulation of WNT5A, the methylation status of the full length of the 5 0 UTR needs to be investigated. We also studied the expression of the three genes in the prostate cancer cell lines LNCaP, DU145 and PC3 (Supplementary Figure 3) . Compared to 1542-NPTX, CRIP1 and WNT5A expression was higher in LNCaP cells. The expression in DU145 and PC3 was similar. WNT5A was found previously to be differentially expressed in 15 ovarian tumor tissues (Matei et al., 2002) .
This study provides evidence of epigenetic regulation of WNT5A. Wnt signaling is involved in tumorigenesis and progression of cancer. Aberrant hypomethylation and overexpression of WNT5A may be functionally important in the progression of prostate cancer.
